Cognitive disorders in persons with hiv-associated meningoencephalitis
pdf

How to Cite

Tovazhnyanska, O., Soloviova, Y., Kauk, O., Nekrasova, N., Markovska, O., & Samoylova, H. (2015). Cognitive disorders in persons with hiv-associated meningoencephalitis. The Journal of Neuroscience, 3(4), 56-59. Retrieved from https://neuroscience.com.ua/index.php/journal/article/view/184

Abstract

Based on a survey of 86 HIV-positive patients undergoing meningoencephalitis different etiology, it has been revealed the influence of inhomogeneous
co-infection on the cognitive sphere. The most pronounced cognitive change identified in a group of survivors of tubercular meningoencephalitis. Were less pronounced cognitive disorders in HIV-infected patients undergoing meningoencephalitis Cytomegalovirus etiology. All patients with moderate dementia had high titres of antibodies to Cytomegalovirus. Therefore, early detection and adequate therapy cognitive dysfunction in HIV-infected patients undergoing meningoencephalitis different etiology, will slow or prevent the onset of cognitive impairment, improve the quality of life of patients and reduce the social burden of acquired immune deficiency syndrome.

pdf

References

1. Antinori A., Arendt G., Becker J.T. et al. Updated research nosology for HIV-associated neurocognitive disorders // Neurology. — 2007. — Vol. 69. — Р. 1789-99.
2. Asch S.M., Kilbourne A.M., Gifford A.L. et al. Underdiagnosis of depression in HIV: who are we missing? // J. Gen. Intern. Med. — 2003. — Vol. 18. — Р. 450-60.
3. Bing E.G., Burnam M.A., Longshore D. et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States // Arch. Gen. Psychiatry. — 2001. — Vol. 58. — Р. 721-28.
4. Cohen M., Hoffman R.G., Cromwell C. et al. The prevalence of distress in persons with human immunodeficiency virus infection // Psychosomatics. — 2002. — Vol. 43. — Р. 10-15.
5. Cherner M., Letendre S., Heaton R.K. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine // Neurology. — 2005. —
Vol. 64 (8). — Р. 1343-1347.
6. Donoghue J. Актовегин в лечении деменции: систематизированный обзор исследований и анализ их результатов с использованием показателя NNT //
Клин. фармакол. тер. — 2013. — № 22 (4). — С. 70-75.
7. Ellis R.J., Deutsch R., Heaton R.K. et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group // Arch. Neurol. — 1997. — Vol. 54. — Р. 416-24.
8. Ellis R., Langford D. and Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair // Nat. Rev. Neurosci. — 2007. — Vol. 8 (1). — Р. 33-44.
9. Elmlinger M.F., Kriebel M., Ziegler D. Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro // Neuromolecular. Med. — 2011. — Vol. 13. — P. 266-274.
10. Gonzalez-Scarano F., Martin-Garcia J. The neuropathogenesis of AIDS // Nat. Rev. Immunol. — 2005. — Vol. 5 (1). — Р. 69-81.
11. Ickovics J.R., Hamburger M.E., Vlahov D. et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study // JAMA. — 2001. — Vol. 285. — Р. 1466-74.
12. Herrmann W.M., Bohn-Olszewsky W.J., Kuntz G. Actovegin infusion treatment in patients with primarily degenerative dementia of the Alzheimer type and multiinfarct dementia // Z. Geriatrie. — 1992. — Vol. 5. — P. 46-55.
13. Hoyer S., Betz K. Elimination of the delayed postischemic energy deficit in cerebral cortex and hippocampus of aged rats with a dried, deproteinized blood extract (Actovegin) // Arch. Gerontol. Geriatr. — 1989. — Vol. 9. — P. 181-192.
14. Hult B., Chana G., Masliah E. et al. Neurobiology of HIV // Int. Rev. Psychiatry. — 2008. — 20 (1). — Р. 3-13.
15. Kanowski S., Kinzler E., Lehmann E. et al. Confirmed clinical efficacy of actovegin in elderly patients with organic brain syndrome // Pharmacopsychiatry Jul. —
1995. — Vol. 28 (4). — P. 125-133.